ArticleZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026
[The consensus of genetic detection in multiple myeloma in China (2026)].
Article in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic abnormalities are a cornerstone for prognostic assessment in multiple myeloma (MM) and form the basis of contemporary risk-stratification systems. In routine clinical practice, cytogenetic karyotyping, fluorescence in situ hybridization, and next-generation sequencing should be performed in a standardized manner to identify high-risk patients and guide individualized therapy. With recent advances in genomic technologies, such as whole-genome sequencing and single-cell sequencing, our understanding of clonal evolution and genetic heterogeneity in MM has deepened. Meanwhile, the use of triplet and quadruplet combination regimens has altered the prognostic impact of certain genetic lesions, highlighting the need to update the existing risk frameworks. To standardize genetic testing for MM in China, the Multiple Myeloma Expert Committee of the Chinese Society of Clinical Oncology (CSCO) and Myeloma & Plasma Cell Disease Group, Hematology Oncology Committee of the China Anti-Cancer Association (CACA) have revised the 2019 consensus based on the latest evidence. This updated consensus focuses on refining the testing workflows, harmonizing the interpretation and reporting of high-risk genetic abnormalities, and discussing the incorporation of emerging molecular markers into risk stratification. This new consensus aims to promote standardized and precision-based MM care in China and improve the identification and management of high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.